Latest News and Press Releases

ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s regulatory filing for ITULATEK® (tree pollen sublingual allergy immunotherapy tablet) for treatment of children and...

Bemærk venligst, at rapporten udelukkende forefindes på  engelsk. ALK delivers 12% organic revenue growth with operating profit up 50% in Q1 Q1 results were strong as expected. Revenue increased on...

ALK delivers 12% organic revenue growth with operating profit up 50% in Q1 Q1 results were strong as expected. Revenue increased on double-digit sales growth in all sales regions, including 22%...

Co-promotion-aftale med ARS Pharma baseret på omkostningsdeling og performance-baseret indtægtsdeling.ALK fremskynder opbygningen af selskabets pædiatriske salgskanal på en balanceret måde.  Aftalen...

Co-promotion with ARS Pharma based on cost sharing and performance-based revenue sharing.ALK to accelerate build-up of its US paediatric sales channel in a balanced way. Agreement does not change...

ALK (ALKB.DC / OMX: ALK B) offentliggør delårsrapport for de første tre måneder af 2025 (Q1) om morgenen tirsdag den 6. maj 2025. ALK afholder senere samme dag kl. 11.00 (CEST) en præsentation for...

ALK (ALKB.DC / OMX: ALK B) will publish its results for the first quarter of 2025 in the morning on Tuesday, 6 May 2025. Later on the same day, the company will host a presentation for investors...

ALK (ALKB.DC / OMX: ALK B) har i dag annonceret, at sundhedsmyndighederne i 17 EU-lande via en type II-variationsprocedure har godkendt selskabets europæiske registreringsansøgning for ITULAZAX®...

ALK (ALKB.DC / OMX: ALK B) today announced that its European regulatory filing for ITULAZAX® (tree pollen sublingual allergy immunotherapy tablet) for treatment of young children and adolescents aged...

ALK (ALKB:DC / OMX: ALK B / AKBLF): I henhold til selskabets vederlagspolitik, som er vedtaget på selskabets ordinære generalforsamling den 14. marts 2024, og i tråd med selskabets sædvanlige praksis...